

October 14, 2015



DelMar Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

- Presentation with live webcast on October 21, 2015 at 3:00 p.m. PDT -

VANCOUVER, British Columbia and MENLO PARK, Calif., Oct. 14, 2015 /PRNewswire/ - [DelMar Pharmaceuticals, Inc.](#) (OTCQX: DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced today that it will present at the 14th Annual [BIO Investor Forum](#) being held October 20-21, 2015 at the Parc 55 Hotel in San Francisco, California.



Jeffrey Bacha, DelMar's president and CEO, will present on Wednesday, October 21, 2015 at 3:00 p.m. Pacific Time. As part of his presentation, Mr. Bacha will present a corporate overview including recent progress of DelMar's Phase II clinical trial of [VAL-083](#) (*dianhydrogalactitol*) for the treatment of refractory glioblastoma multiforme (GBM). He will also discuss the Company's plans to initiate clinical trials with [VAL-083 as a potential treatment for non-small cell lung cancer](#) (NSCLC) and other solid tumors in collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd.

DelMar is conducting a multicenter Phase I/II clinical study with VAL-083 in patients with recurrent GBM. [Data from the Phase I dose-escalation portion of the trial was presented at ASCO](#). Dose limiting toxicity was observed at a dose of 50mg/m²/day; no drug-related severe adverse events were reported and myelosuppression was mild at doses $\leq 40\text{mg/m}^2/\text{day}$. Preliminary analysis suggested a dose-dependent and clinically meaningful survival benefit in GBM patients whose tumors had progressed following standard treatment with temozolomide, radiotherapy, bevacizumab and a range of salvage therapies.

The Company recently presented an update from the GBM clinical study at GBM2015 on a sub-group analysis for patients receiving up to 5 mg/m² daily x 3 every 21 days (low dose) versus those patients receiving 30mg/m² or 40mg/m² (high dose) of VAL-083. In this analysis [VAL-083 demonstrates dose-response and survival benefit in GBM patients failing standard front-line therapy and bevacizumab](#).

A live audio webcast will be available by accessing DelMar's [IR Calendar](#) in the [Investors](#)

section of the Company's website (www.DelMarPharma.com). A webcast replay will be available approximately two hours after the presentation and will be accessible for one month.

About BIO

[BIO](#) is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. The 14th Annual [BIO Investor Forum](#) is an international biotech investor conference focused on early and established private companies as well as emerging public companies. BIO also produces the [BIO International Convention](#), the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

About VAL-083

VAL-083 is a "first-in-class," small-molecule chemotherapeutic. In more than 40 Phase I and II clinical studies sponsored by the U.S. National Cancer Institute, VAL-083 demonstrated safety and efficacy in treating a number of cancers including lung, brain, cervical, ovarian tumors and leukemia. VAL-083 is approved in China for the treatment of chronic myelogenous leukemia (CML) and lung cancer, and has received orphan drug designation in Europe and the U.S. for the treatment of gliomas.

DelMar is currently studying VAL-083 in a multi-center Phase I/II clinical trial for patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of brain cancer. DelMar has demonstrated that VAL-083's anti-tumor activity is unaffected by the expression of MGMT, a DNA repair enzyme that is implicated in chemotherapy resistance and poor outcomes in GBM patients following standard front-line treatment with Temodar[®] (temozolomide).

The trial is being conducted in accordance with the protocol that has been filed with the U.S. Food and Drug Administration (FDA) at five clinical centers in the United States: Mayo Clinic (Rochester, MN); UCSF (San Francisco, CA) and three centers associated with the Sarah Cannon Cancer Research Institute (Nashville, TN, Sarasota, FL and Denver, CO). Further details can be found at <http://www.delmarpharma.com/clinical-trial.html>.

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For further information, please visit <http://delmarpharma.com/>; or contact DelMar Pharmaceuticals Investor Relations: ir@delmarpharma.com / (604) 629-5989. Connect with the Company on [Twitter](#), [LinkedIn](#), [Facebook](#), and [Google+](#). Investor Relations Counsel: Amato & Partners LLC.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our current reports on Form 8-K.

Logo - <https://photos.prnewswire.com/prnh/20150909/265198LOGO>

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/delmar-pharmaceuticals-to-present-at-the-14th-annual-bio-investor-forum-300158799.html>

SOURCE DelMar Pharmaceuticals, Inc.